Oral Semaglutide's Real-World Efficacy in T2DM Patients Transitioning from DPP-4i Explored
Background
Type 2 Diabetes Mellitus (T2DM) management often involves a stepwise approach, with dipeptidyl peptidase-4 inhibitors (DPP-4i) being a common early-line therapy due to their good tolerability and moderate efficacy in improving glycemic control by enhancing endogenous incretin action. However, many patients eventually experience inadequate glycemic control on DPP-4i monotherapy or combination therapy, necessitating treatment escalation. Glucagon-like peptide-1 receptor (GLP-1R) agonists, like semaglutide, offer potent glycemic reduction, weight loss benefits, and cardiovascular protection, making them an attractive option for intensification. Understanding the real-world effectiveness and patient experience when transitioning from DPP-4i to oral semaglutide is crucial for optimizing treatment strategies and patient outcomes.
Study Design
The DOORS study is a 40-week, observational, prospective study conducted in Italy. It aims to evaluate the real-world clinical outcomes in adults with type 2 diabetes mellitus who transitioned to oral semaglutide after achieving inadequate glycemic control on prior DPP-4i treatment. Participants will receive oral semaglutide as prescribed by their study doctor, with no specific dose or frequency mandated by the protocol, reflecting real-world clinical practice. Primary endpoints include changes in glycaemic control (likely measured by HbA1c), weight management, and patient-reported outcomes (PROs) assessed via two questionnaires on eating behavior and diabetes-related aspects. Health questions and lab tests will be collected during normal scheduled visits.
Results
As an ongoing observational study, specific findings and numerical results are not yet available. The study is designed to collect real-world data on the effectiveness of transitioning from DPP-4i to oral semaglutide in a clinical setting. The primary outcomes of glycaemic control, weight management, and patient-reported outcomes will be analyzed upon study completion.
Why It Matters
Understanding the real-world benefits of switching from DPP-4i to oral semaglutide is critical for clinicians and patients managing T2DM. This study will provide valuable insights into how oral semaglutide performs in patients who have not achieved sufficient glycemic control with DPP-4i, offering practical guidance for treatment intensification. The inclusion of patient-reported outcomes will highlight the impact on quality of life and eating behaviors, which are often overlooked but crucial for long-term adherence and satisfaction. This data could inform future clinical guidelines, potentially streamlining the transition process and improving patient care by demonstrating the tangible advantages of this therapeutic switch in a real-world setting.
semaglutide
oral semaglutide
type 2 diabetes
dpp-4i
glycemic control
weight management